Geron Corp. Stock
Geron Corp. Stock
A very strong showing by Geron Corp. today, with an increase of €0.39 (11.110%) compared to yesterday's price.
Geron Corp. is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
As a result the target price of 4 € shows a slightly positive potential of 3.71% compared to the current price of 3.86 € for Geron Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Geron Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Geron Corp. in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Geron Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Geron Corp. | 11.110% | 2.018% | 15.924% | 64.100% | 79.776% | 183.040% | 114.554% |
| Ardelyx Inc. | -0.970% | -1.640% | -11.302% | 48.049% | 3.737% | -18.973% | - |
| Salarius Pharmaceuticals Inc. | -1.840% | 1.429% | 0.472% | -70.417% | -23.243% | -98.377% | -99.993% |
| Brainstorm Cell | -5.760% | -2.456% | -5.429% | -82.011% | 114.009% | -83.450% | - |
Comments
Geron Co. (NASDAQ: GERN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
News
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. (NASDAQ: GERN) is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their
Geron (GERN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q4 2023 Earnings CallFeb 28, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Geron (GERN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q3 2023 Earnings CallNov 02, 2023, 9:00 a.m. ET
Operator
Source Fool.com